On December 17, 2025, Kalaris Therapeutics announced initial positive data from its Phase 1a clinical trial of TH103 for neovascular age-related macular degeneration, showing significant vision improvements and well-tolerated administration in treatment-naïve patients. The trial revealed a mean 10-letter improvement in best corrected visual acuity and significant reductions in retinal fluid without major adverse effects, suggesting TH103 may have extended treatment durability.